These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38045044)

  • 1. Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma.
    Liu Y; Zhan Z; Kang Z; Li M; Lv Y; Li S; Tong L; Feng F; Li Y; Zhang M; Xue Y; Chen Y; Zhang T; Song P; Su Y; Shen Y; Sun Y; Yang X; Chen Y; Yao S; Yang H; Wang C; Geng M; Li W; Duan W; Xie H; Ding J
    Acta Pharm Sin B; 2023 Dec; 13(12):4748-4764. PubMed ID: 38045044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors.
    Kang Z; Li S; Lin Y; Li Y; Mao Y; Zhang J; Lei T; Wang H; Su Y; Yang Y; Qiu J; Li W
    Invest New Drugs; 2023 Apr; 41(2):296-305. PubMed ID: 36884148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
    Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
    PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
    Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
    Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
    [No Abstract]   [Full Text] [Related]  

  • 7. The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.
    Jensen KV; Cseh O; Aman A; Weiss S; Luchman HA
    PLoS One; 2017; 12(12):e0189670. PubMed ID: 29253028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of anti-angiogenic agent F16 for targeting glioblastoma xenograft tumors.
    Algahtani M; Natarajan U; Alhazzani K; Alaseem A; Rathinavelu A
    Cancer Genet; 2022 Jun; 264-265():71-89. PubMed ID: 35568001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
    Stazi G; Taglieri L; Nicolai A; Romanelli A; Fioravanti R; Morrone S; Sabatino M; Ragno R; Taurone S; Nebbioso M; Carletti R; Artico M; Valente S; Scarpa S; Mai A
    Clin Epigenetics; 2019 Dec; 11(1):173. PubMed ID: 31791385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy.
    Zou Y; Wang Y; Xu S; Liu Y; Yin J; Lovejoy DB; Zheng M; Liang XJ; Park JB; Efremov YM; Ulasov I; Shi B
    Adv Mater; 2022 Aug; 34(33):e2203958. PubMed ID: 35738390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
    Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
    J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression.
    Zhao W; Yun K
    Exp Cell Res; 2022 Sep; 418(2):113277. PubMed ID: 35810776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-brain barrier penetrating liposomes with synergistic chemotherapy for glioblastoma treatment.
    Zhang Y; Qu H; Xue X
    Biomater Sci; 2022 Jan; 10(2):423-434. PubMed ID: 34873606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma.
    Ozawa T; Rodriguez M; Zhao G; Yao TW; Fischer WN; Jandeleit B; Koller K; Nicolaides T
    Cureus; 2021 Aug; 13(8):e17595. PubMed ID: 34646647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
    Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
    Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.
    Kim SS; Rait A; Kim E; Pirollo KF; Nishida M; Farkas N; Dagata JA; Chang EH
    ACS Nano; 2014 Jun; 8(6):5494-514. PubMed ID: 24811110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
    Kim SS; Rait A; Kim E; Pirollo KF; Chang EH
    Nanomedicine; 2015 Feb; 11(2):301-11. PubMed ID: 25240597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioblastoma genetic drivers dictate the function of tumor-associated macrophages/microglia and responses to CSF1R inhibition.
    Rao R; Han R; Ogurek S; Xue C; Wu LM; Zhang L; Zhang L; Hu J; Phoenix TN; Waggoner SN; Lu QR
    Neuro Oncol; 2022 Apr; 24(4):584-597. PubMed ID: 34562087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.